The Markey Cancer Center (MCC), a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK Healthcare enterprise, has undergone dramatic expansion in recent years under the leadership of MCC Director Dr. B. Mark Evers. At this point in the center's development, the MCC seeks support through the National Cancer Institute (NCI) Cancer Center Support Grant to capitalize on this momentum and to drive a measurable reduction in cancer mortality in Kentucky, particularly Appalachian Kentucky, through a comprehensive program of cancer research, prevention, and patient care. The need for NCI Cancer Center designation is particularly acute in a state that leads the nation across numerous cancer indicators, including the highest rate of cancer deaths in the nation. Situated on a campus with all six health professions colleges in proximity to each other, the MCC offers a history of rich transdisciplinary collaboration, an outstanding program of cancer prevention and control that has produced seminal work in Appalachian Kentucky, nationally acclaimed basic research programs in cancer biology and DNA repair and oxidative stress, and a translational therapeutics program complemented by a top five College of Pharmacy. These strengths have coalesced in MCC's four thematic research programs: Cancer Cell Biology and Signaling;Cancer Prevention and Control;Drug Discovery, Delivery and Translational Therapeutics;and Redox Injury and Repair. Currently, the MCC's 108 Research and Associate Research members hold appointments in 24 departments in 7 colleges across the university (25 new faculty were recruited in the last 3 years). MCC members hold grants for 144 research projects funded in the annual composite (direct + indirect) amount of more than $30.5 million, of which over $11.3 million (37%) comes from the NCI. Accrual to therapeutic clinical trials has increased over 130% in three years, and MCC assignable space has increased 40%, including a doubling of state-of-the-art research space. In addition, six shared resources facilitate cutting-edge research by providing a robust infrastructure for specialized expertise and advanced methods. They include: Biospecimen and Tissue Procurement;Biostatistics;Cancer Research Informatics;Clinical Research and Data Management;Flow Cytometry and Cell Sorting;and Free Radical Biology in Cancer. The MCC is currently well positioned to take on new challenges and to continue to evolve in key strategic directions that take maximum advantage of these strengths.

Public Health Relevance

As a state with the second highest all-site cancer Incidence rate and the highest rate of cancer deaths in the United States, Kentucky suffers from particularly intractable cancer health challenges. The Markey Cancer Center seeks support to further develop its capacities in cutting-edge science to accelerate bench to bedside translational outcomes, which will reduce this serious health disparity and significantly impact our patients, our state, and the nation through cancer prevention, patient care, and research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA177558-02S1
Application #
8791154
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2013-07-08
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$75,000
Indirect Cost
$25,000
Name
University of Kentucky
Department
Surgery
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Jarrett, Stuart G; Carter, Katharine M; Bautista, Robert-Marlo et al. (2018) Sirtuin 1-mediated deacetylation of XPA DNA repair protein enhances its interaction with ATR protein and promotes cAMP-induced DNA repair of UV damage. J Biol Chem 293:19025-19037
Al-Darraji, Ahmed; Haydar, Dalia; Chelvarajan, Lakshman et al. (2018) Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease. PLoS One 13:e0200474
Choi, Yohan; Rosewell, Katherine L; Brännström, Mats et al. (2018) FOS, a Critical Downstream Mediator of PGR and EGF Signaling Necessary for Ovulatory Prostaglandins in the Human Ovary. J Clin Endocrinol Metab 103:4241-4252
Zaytseva, Yekaterina Y; Rychahou, Piotr G; Le, Anh-Thu et al. (2018) Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget 9:24787-24800
Dhar, Sanjit K; Bakthavatchalu, Vasudevan; Dhar, Bithika et al. (2018) DNA polymerase gamma (Pol?) deficiency triggers a selective mTORC2 prosurvival autophagy response via mitochondria-mediated ROS signaling. Oncogene 37:6225-6242
Jiang, Kai; Liu, Yajuan; Zhang, Jie et al. (2018) An intracellular activation of Smoothened that is independent of Hedgehog stimulation in Drosophila. J Cell Sci 131:
Engle, Jeff A; Traynor, Anne M; Campbell, Toby C et al. (2018) Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center. J Oncol Pharm Pract 24:348-353
Kim, Ji Tae; Napier, Dana L; Weiss, Heidi L et al. (2018) Neurotensin Receptor 3/Sortilin Contributes to Tumorigenesis of Neuroendocrine Tumors Through Augmentation of Cell Adhesion and Migration. Neoplasia 20:175-181
Gedaly, Roberto; De Stefano, Felice; Turcios, Lilia et al. (2018) mTOR Inhibitor Everolimus in Regulatory T cell Expansion for Clinical Application in Transplantation. Transplantation :
Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89

Showing the most recent 10 out of 359 publications